Abstract: A polypeptide drug conjugate, a compound represented by formula (V) and an application thereof are provided.

Abstract: A glucoside derivative that acts as an SGLT1 inhibitor and an application thereof in the preparation of a drug for SGLT1 related diseases. Specifically disclosed is a compound represented by formula (II), a tautomer thereof or a pharmaceutically acceptable composition thereof.

Abstract: A series of macrocyclic amide compounds and an application thereof. Specifically disclosed are a compound as represented by formula (V) or a pharmaceutically acceptable salt thereof and an application thereof.

Abstract: Disclosed are a non-fluorinated quinolone compound and use thereof, specifically relating to a compound represented by formula (II) and a pharmaceutically acceptable salt thereof.

Abstract: A class of benzoxazinone derivatives and a preparation method therefor, specifically related to a compound shown in formula (II), or a stereoisomer or a pharmaceutically acceptable salt thereof.

Abstract: The present invention provides crystalline forms of a compound of formula (I): Also provided are pharmaceutical compositions that include the provided crystalline forms and methods of using the provided crystalline forms and pharmaceutical compositions for the treatment of cancer.

Abstract: The invention relates to certain substituted 3-dialkylaminomethyl-piperidin-4-yl-benzamides, and compositions comprising the same, which in certain embodiments are useful for treating and/or preventing pain in a subject in need thereof.

Abstract: The present disclosure relates, in general, to use of small diffusible thiols in the treatment of neurodegenerative diseases associated with glutamate excitotoxicity, protein aggregation and oxidative stress in the central nervous system, particularly in the brain.

Abstract: A series of deuterated nucleoside compounds are compounds represented by formula (IV), and stereoisomers or pharmaceutically acceptable salts thereof.

Abstract: The present application relates to a pyrimidopyran compound, and specifically discloses a compound as represented by formula (III), and a pharmaceutically acceptable salt thereof.

Abstract: A heteroaryl-3-piperidinedione compound and the use thereof. Particularly disclosed are a compound represented by formula (II) and a pharmaceutically acceptable salt thereof.

Abstract: The present invention provides, inter alia, methods, kits, and pharmaceutical compositions for treating or ameliorating the effects of a cancer in a subject in need thereof. The method comprises administering to the subject an effective amount of (i) a first anti-cancer agent, which is BVD-523 or a pharmaceutically acceptable salt thereof and (ii) a second anti-cancer agent, which is a CDK inhibitor or a pharmaceutically acceptable salt thereof, to treat or ameliorate the effects of the cancer. Additional methods for effecting cancer cell death are also provided.

Abstract: Disclosed are a series of deuterated nucleoside compounds and a use thereof. Specifically disclosed are compounds represented by formula (VI-2), and stereoisomers or pharmaceutically acceptable salts thereof.

Abstract: Disclosed are a series of deuterated nucleoside compounds and a use thereof. Specifically disclosed are compounds represented by formula (VI-1), stereoisomers or pharmaceutically acceptable salts thereof.

Abstract: The present invention relates to a group of pyrrolo[2,1-f][1,2,4]triazine derivatives serving as selective HER2 inhibitors and an application thereof in the preparation of a drug that serves as an HER2 inhibitor. Specifically, the present invention relates to a compound represented by formula (I), an isomer thereof or a pharmaceutically acceptable salt thereof.

Abstract: A bicyclic substituted aromatic carboxylic acid compound, in particular a compound as represented by formula (I) and a pharmaceutically acceptable salt thereof. In formula (I), R2 and R3 and atoms connected thereto together form a 3-6 membered heterocyclic group, or R2 and R4 and atoms connected thereto together form a 3-6 membered heterocyclic group. The compound has obvious inhibitory activity on activation of a human serum alternative pathway and significant binding activity to human complement Factor B protein, and also has relatively good in-vivo pharmacodynamic and pharmacokinetic properties.

Abstract: An apparatus and method for identifying single points of failure are described. The apparatus includes at least a processor and a memory communicatively coupled to the at least a processor. The memory includes instructions configuring the at least a processor to receive digital resource data for a plurality of digital resources linked to a computing environment, generate a plurality of dependency trees for the plurality of digital resources, determine at least one common digital resource from each of the plurality of dependency trees, and identify a single point of failure from the at least one common digital resource.

Abstract: Provided are pyrimidine aromatic ring compounds. Specifically provided is a compound as represented by formula (II) or a pharmaceutically acceptable salt thereof.

Abstract: The present invention relates to a series of fused ring derivatives containing 1,4-oxazepane and a preparation method therefor, and in particular relates to a compound as shown in formula (II) and a pharmaceutically acceptable salt thereof.

Abstract: Modified forms of hemagglutinin (HA) protein including those with modified immunodominant regions and with modified maturation cleavage sites, and virus and virus-like particles containing them are disclosed.